Latest News You are here:HomeOur servicesList of servicesInflammatory Bowel Disease ServiceLatest News April 2025 - PBS listing of high concentration adalimumab (Hyrimoz®) 40 mg/0.4mL in syringe presentation, in addition to existing pen device. Hyrimoz® storage information has been updated to allow for storage at room temperature (25°C) for up to 42 days once removed from the refrigerator. March 2025 - New Australian Government Department of Health Pharmaceutical Benefits Scheme - Biosimilar Adalimumab medicine fact sheet February 2025 - Release of Crohn's & Colitis Australia State of the Nation in Inflammatory Bowel Disease in Australia: Summary Report October 2024 - PBS listing of etrasimod (Velsipity®) for ulcerative colitis September 2024 - Expansion of shingles (Shingrix®) vaccination eligibility criteria under the National Immunisation Program. Eligible people now includes individuals 18 years and over considered at increased risk of herpes zoster due to specified underlying condition and/or immunomodulatory/immunosuppressive treatments. Ask the IBD team or GP regarding eligibility. July 2024 - Adalimumab (Humira® and Hyrimoz®) 40mg weekly maintenance dosing now available to be accessed via the PBS for patients living with luminal Crohn's disease or ulcerative colitis 17th May 2024 – TGA approval of etrasimod (Velsipity®) for ulcerative colitis 18th January 2024 – TGA approval of ustekinumab biosimilar (Wezlana®) for Crohn’s disease and ulcerative colitis 3rd January 2024 – PBS listing of ustekinumab (Stelara®) for fistulising Crohn’s disease 1st December 2023 – PBS listing of upadacitinib (Rinvoq®) for Crohn’s disease 1st May 2023 – PBS listing of upadacitinib (Rinvoq®), ozanimod (Zeposia®) and ustekinumab (Stelara®) for ulcerative colitis Patient Information and Resources Smoking Quit smoking and vaping